Equities

Globus Medical Inc

Globus Medical Inc

Actions
  • Price (MXN)1,341.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Sep 27 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Globus Medical Inc had net income fall -35.39% from 190.17m to 122.87m despite a 53.34% increase in revenues from 1.02bn to 1.57bn. An increase in the cost of goods sold as a percentage of sales from 25.78% to 34.95% was a component in the falling net income despite rising revenues.
Gross margin58.14%
Net profit margin3.69%
Operating margin4.67%
Return on assets1.75%
Return on equity2.22%
Return on investment1.99%
More ▼

Cash flow in USDView more

In 2023, Globus Medical Inc increased its cash reserves by 210.56%, or 316.83m. Cash Flow from Investing totalled 302.97m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 243.50m in cash from operations while cash used for financing totalled 231.82m.
Cash flow per share2.55
Price/Cash flow per share38.50
Book value per share29.94
Tangible book value per share13.21
More ▼

Balance sheet in USDView more

Globus Medical Inc has a Debt to Total Capital ratio of 9.74%, unchanged from the previous year.
Current ratio2.51
Quick ratio1.64
Total debt/total equity0.1079
Total debt/total capital0.0974
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-7.04
EPS (TTM) vs
TTM 1 year ago
-57.08
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.